Temporal trends in small cell lung cancer: Analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database

Abstract

7082 Background: Research interest in small cell lung cancer (SCLC) has waned over the past 10 years due to the lack of significant therapeutic advances and a presumed decline in the incidence of SCLC. Methods: We analyzed data on all patients with primary bronchogenic carcinoma registered in the national SEER database from 1973–2002. To identify temporal trends, the study period was divided into three decades: 1973–1982 (D1), 1983–1992 (D2), and 1993–2002 (D3). Results: Of 318,584 eligible patients, 59,704 (18.7%) had SCLC. The proportional incidence of SCLC relative to non-SCLC was higher in Caucasians than African-Americans (19.6% vs 13.9%), women vs men (21% vs 17.4%), and patients ≥ 50 yrs old vs < 50 yrs old (18.9% vs 16%). By decade, the proportional incidence of SCLC was: D1, 18.4%; D2, 19.8%; D3, 17.9%. The overall incidence rates for both SCLC and non-SCLC initially rose and then declined during the study period. The incidence rates for SCLC were similar in both Caucasians and African-Americans throughout the study period, while those for non-SCLC were significantly higher in African-Americans. The gap between incidence rates in men and women has narrowed to a similar degree for both SCLC (M/F: D1, 2.6/1 to D3 1.4/1) and NSCLC (M/F: D1, 3.3/1 to D3, 1.7/1). Only 0.8% of SCLC patients underwent surgical resection from 1988–2002. The use of radiotherapy decreased during the study period (D1, 53% to D3, 43%) with greater use in younger patients and African-Americans. Stage-specific 2- and 5-year survival rates for SCLC improved over time (regional 2-yr/5-yr: D1, 15%/6.8% to D3, 22%/11%; distant 2-yr/5-yr: D1, 3.4%/1.3% to D3, 5.6%/1.9%). In multivariate analysis, significant favorable prognostic factors included: younger age, Caucasian race, female gender, limited stage, and later year of diagnosis. Conclusions: The proportional incidence of SCLC has declined only slightly over the past three decades. While overall survival has modestly improved, SCLC remains a major public health problem. No significant financial relationships to disclose.

KIF5B‐RET fusions in Chinese patients with non–small cell lung cancer

“…In addition, RET gene abnormalities are closely associated with the pathogenesis of neuroendocrine tumors [24][25][26] ; and, among these, thyroid cancer is the most typical. Also, lung neuroendocrine tumors account for approximately 20% of lung cancers and are classified as high-grade (approximately 15% of lung cancers), [27][28][29] intermediate-grade, and low-grade neuroendocrine carcinoma (accounting for 1%-2% of lung cancers). 30,31 One KIF5B-RET fusion-positive patient in our current study was diagnosed with low-grade neuroendocrine carcinoma (typical carcinoids); and, again, our findings demonstrated a close correlation between RET gene abnormality and neuroendocrine tumors.…”

New Advances in the Second-Line Treatment of Small Cell Lung Cancer

“…Despite recent advances in management strategies for SCLC, improvements in survival have been small, and prognosis remains poor, with 5-year survival rates for LS and ES disease of around 10% and 2%, respectively [12]. This reflects the fact that, although SCLC is initially a chemosensitive disease (with response rates to first-line treatment on the order of 70%-90% in LS disease and 50%-60% in ES disease [13]), development of resistance to treatment is a major problem.…”

Combination wt-p53 and MicroRNA-125b Transfection in a Genetically Engineered Lung Cancer Model Using Dual CD44/EGFR-targeting Nanoparticles

“…Lung cancer is the leading cause of cancer deaths worldwide, and non-small-cell lung cancers (NSCLC) accounts for majority (>85%) of all the lung cancer cases. [1][2][3] Cisplatin is often used in combination with other cytotoxic agents, such as etoposide or gemcitabine, as the first-line treatment of advanced NSCLC in the clinic. However, due to the rapid acquisition of multidrug resistance in NSCLC, alternative therapeutic strategies are in critical demand and being fervently explored in preclinical and clinical settings.…”